Archives of the Turkish Society of Cardiology
Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2018; 46(8): 659-666 | DOI: 10.5543/tkda.2018.62678

Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease

Ali Çoner1, Davran Çiçek1, Sinan Akıncı1, Serhat Balcıoğlu1, Cihan Altın2, Haldun Müderrisoğlu3
1Department of Cardiology, Başkent University Hospital, Alanya Medical and Research Center, Alanya, Turkey
2Department of Cardiology, Başkent University Hospital, İzmir Zübeyde Hanım Medical and Research Center, İzmir, Turkey
3Department of Cardiology, Başkent University Hospital, Ankara, Turkey


OBJECTIVE
Diffuse coronary artery disease (CAD) is a challenging issue in clinical cardiology practice. There are limited data about percutaneous revascularization in these patients.

METHODS
This study was an observational clinical evaluation. The records of patients with diffuse CAD revascularized with new-generation drug-eluting stents (DES) were researched retrospectively. Patients treated with multiple, overlapping new-generation DES (at least 60mm in length per vessel) were included. The incidence of major adverse cardiac events (MACE), defined as cardiac death, stent thrombosis, non-fatal myocardial infarction, and target lesion revascularization (TLR), at the end of the first year following the index procedure was recorded.

RESULTS
A total of 71 patients (with 75 coronary vessels) treated with new-generation DES for diffuse CAD were enrolled in the study. Zotarolimus-eluting stents were used in 48 vessels and biolimus A9-eluting stents were used in 27 vessels. The median total stent length per vessel was 75.0 mm (60.0–106.0) and the median number of stents implanted was 3 (2–4) for each vessel. The cumulative incidence of MACE at the end of the first year was 11.2% (8 patients). The presence of diabetes mellitus (DM) and ST-segment elevated myocardial infarction (STEMI) were defined as independent clinical risk factors related to MACE development.

CONCLUSION
Coronary artery revascularization with new-generation drug-eluting stents can be a good choice in the treatment of selected patients with diffuse CAD. DM and STEMI were found to be related to poorer clinical outcomes with this treatment option in our study.

Keywords: Diffuse coronary artery disease, drug-eluting stents, percutaneous coronary intervention.

How to cite this article
Ali Çoner, Davran Çiçek, Sinan Akıncı, Serhat Balcıoğlu, Cihan Altın, Haldun Müderrisoğlu. Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease. Turk Kardiyol Dern Ars. 2018; 46(8): 659-666

Corresponding Author: Ali Çoner, Türkiye
© Copyright 2018 Archives of the Turkish Society of Cardiology
LookUs & Online Makale